The Experts below are selected from a list of 5256 Experts worldwide ranked by ideXlab platform
R F Degenring - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal Triamcinolone Acetonide for treatment of intraocular proliferative exudative and neovascular diseases
Progress in Retinal and Eye Research, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, R F DegenringAbstract:Abstract Within the last three years, Triamcinolone Acetonide has increasingly been applied intravitreally as treatment option for various intraocular neovascular edematous and proliferative disorders. The best response in terms of gain in visual acuity after the intravitreal injection of Triamcinolone Acetonide was found in eyes with intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. Visual acuity increased and degree of intraocular inflammation decreased in eyes with various types of non-infectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis–Behcet's disease. Intravitreal Triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularization and proliferative ischemic retinopathies. Possibly, intravitreal Triamcinolone may be helpful as adjunct therapy for exudative age-related macular degeneration, possibly in combination with photodynamic therapy. In eyes with chronic, therapy resistant, ocular hypotony, intravitreal Triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal Triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataractogenesis, postoperative infectious and non-infectious endophthalmitis, and pseudo-endophthalmitis. Intravitreal Triamcinolone injection can be combined with other intraocular surgeries including cataract surgery. Cataract surgery performed some months after the injection does not show a markedly elevated rate of complications. If vision increases and eventually decreases again after an intravitreal Triamcinolone Acetonide injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of Triamcinolone depended on the dosage given. Given in a dosage of about 20 mg to non-vitrectomized eyes, the duration of the effect and of the side-effects was 6–9 months. Intravitreal Triamcinolone Acetonide may offer a possibility for adjunctive treatment of intraocular edematous and neovascular disorders. One has to take into account the side-effects and the lack of long-term follow-up observations.
-
intraocular pressure elevation after intravitreal Triamcinolone Acetonide injection
Ophthalmology, 2005Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone Acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone Acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone Acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone Acetonide therapy.
-
branch retinal vein occlusion treated by intravitreal Triamcinolone Acetonide
Eye, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Bernd A Kamppeter, Imren Akkoyun, R F DegenringAbstract:To evaluate the effect of intravitreal Triamcinolone Acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20–25 mg of Triamcinolone Acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7±4.4 months. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27±0.11 preoperatively to a best postoperative visual acuity of 0.45±0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18±0.18 to 0.13±0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29±0.09 to 0.53±0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Intravitreal injection of Triamcinolone Acetonide can increase visual acuity in patients with branch retinal vein occlusion.
-
Duration of the effect of intravitreal Triamcinolone Acetonide as treatment for diffuse diabetic macular edema
American journal of ophthalmology, 2004Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Bernd A Kamppeter, Imren AkkoyunAbstract:Abstract Purpose To evaluate the duration of the effect of intravitreal Triamcinolone Acetonide on visual acuity in patients with diffuse diabetic macular edema. Design Clinical interventional case series. Methods Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg Triamcinolone Acetonide. Mean follow-up time was 13.2 ± 6.0 months (6.03–25.2 months). Results Visual acuity and intraocular pressure began to increase significantly ( P = .003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection. Conclusions The effect of an intravitreal injection of approximately 20- to 25-mg Triamcinolone Acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal Triamcinolone Acetonide for the treatment of diffuse diabetic macular edema.
-
intravitreal Triamcinolone Acetonide for pseudophakic cystoid macular edema
American Journal of Ophthalmology, 2003Co-Authors: Jost B Jonas, Ingrid Kreissig, R F DegenringAbstract:Abstract Purpose To report the clinical outcome of patients undergoing intravitreal injection of Triamcinolone Acetonide as treatment of long-standing cystoid macular edema after phacoemulsification. Design Prospective clinical interventional cases series studies. Methods The study included five patients suffering from cystoid macular edema after cataract surgery. They received an intravitreal injection of 25-mg crystalline Triamcinolone Acetonide transconjunctivally with topical anesthesia. Results In the follow-up period of 6.6 ± 4.1 months, visual acuity increased from 0.26 ± 0.13 to a mean maximal visual acuity of 0.60 ± 0.19. For all patients, visual acuity improved during the follow-up by at least 0.20. Two (40%) patients developed intraocular pressure values higher than 21 mm Hg, which could be controlled by topical antiglaucomatous treatment. Conclusions Intravitreal Triamcinolone Acetonide may be a therapeutic option for long-standing cystoid macular edema after cataract surgery.
Jost B Jonas - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal Triamcinolone Acetonide for treatment of acute nonarteritic anterior ischemic optic neuropathy
Graefes Archive for Clinical and Experimental Ophthalmology, 2007Co-Authors: Jost B Jonas, Ulrich H M Spandau, Bjoern Harder, Gangolf SauderAbstract:Purpose To report on the use of intravitreal Triamcinolone Acetonide as treatment for nonarteritic anterior ischemic optic neuropathy (NAION).
-
intraocular pressure elevation after intravitreal Triamcinolone Acetonide injection
Ophthalmology, 2005Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone Acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone Acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone Acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone Acetonide therapy.
-
inter eye difference in diabetic macular edema after unilateral intravitreal injection of Triamcinolone Acetonide
American Journal of Ophthalmology, 2004Co-Authors: Jost B Jonas, B Harder, Bernd A KamppeterAbstract:Purpose To report on visual outcome of patients receiving intravitreal Triamcinolone Acetonide for treatment of diffuse diabetic macular edema. Design Prospective, comparative clinical interventional study. Methods setting: Institutional. patient population: The study included 25 consecutive patients (50 eyes) with bilateral diabetic macular edema. intervention procedure: Unilateral intravitreal injection of about 20 mg Triamcinolone Acetonide into the eye (study group) more severely affected by diabetic maculopathy. The contralateral eyes served as control group. Mean follow-up was 7.1 ± 4.1 months. main outcome measure: Visual acuity, intraocular pressure. Results In the study group, visual acuity increased significantly ( P ≤ .001) by 3.0 ± 2.6 Snellen lines to a peak at two to six months after the injection, and decreased significantly ( P = .001) towards the end of follow up. At the end of follow-up, visual acuity was higher, not significantly ( P = .18) higher, than at baseline. An increase in visual acuity was found in 23 eyes (92%). In the control group, differences between visual acuity at baseline and at any of the re-examinations during follow-up were not significant ( P > .10). In an intra-individual inter-eye comparison, gain in visual acuity was significantly ( P Conclusions Intravitreal Triamcinolone Acetonide may temporarily increase visual acuity in eyes with diabetic macular edema.
-
intravitreal Triamcinolone Acetonide for treatment of sympathetic ophthalmia
American Journal of Ophthalmology, 2004Co-Authors: Jost B JonasAbstract:PURPOSE: To report on the treatment of long-standing sympathetic ophthalmia by intravitreal Triamcinolone Acetonide. DESIGN: Clinical interventional case report. METHODS: A 47-year-old patient who suffered from sympathetic ophthalmia and who was treated with intensive systemic immunosuppressive therapy received an intravitreal injection of 25 mg of Triamcinolone Acetonide. Before injection, intraocular pressure ranged between 5 and 8 mm Hg; visual acuity measured 6/20. RESULTS: Within the first 4 weeks after the injection, visual acuity improved from 6/20 to 6/12, intraocular pressure increased to values between 10 mm Hg and 13 mm Hg, and intraocular flare measurements decreased by approximately 50%. Systemic immunosuppressive treatment was reduced to 10 mg prednisolone/day at the first postoperative day and could not be stopped due to an adrenal insufficiency. Three months after the injection, visual acuity regressed to 6/20, intraocular pressure was reduced to values between 5 mm Hg and 10 mm Hg, and anterior chamber flare increased. The patient received a second intravitreal injection of 25 mg of Triamcinolone Acetonide after which intraocular pressure increased again to values between 10 mm and 13 mm Hg, and anterior chamber flare decreased. After the injection, perimetry revealed a marked enlargement of the originally constricted visual field with a decrease in mean visual field defect from approximately 11 dB to values lower than 7 dB. CONCLUSIONS: Intravitreal injections of Triamcinolone Acetonide may be an additional tool in the treatment for sympathetic ophthalmia.
-
Intraocular availability of Triamcinolone Acetonide after intravitreal injection.
American journal of ophthalmology, 2004Co-Authors: Jost B JonasAbstract:Abstract Background To evaluate the intraocular concentration of Triamcinolone Acetonide after intravitreal injection. Methods The prospective clinical interventional case series study included 17 patients who had received a 20 to 25-mg intravitreal injection of Triamcinolone Acetonide as treatment for exudative age-related macular degeneration, diffuse diabetic macular edema, or retinal vein occlusions. During a secondary intraocular surgery taking place 4.1 weeks to 25.7 months after the intravitreal injection, aqueous humor samples were obtained. None of the eyes were vitrectomized. Results In the aqueous humor samples, Triamcinolone Acetonide was in low, but measurable, concentrations detected up to 1.5 years after the intravitreal injection. Concentrations found in samples obtained during the first 6 months, or 7 to 12 months, respectively, after the injection ranged between 3.0 μg/l and 436 μg/l, and between 0.0 μg/l and 11.2 μg/l, respectively. Conclusions After injection of Triamcinolone Acetonide, Triamcinolone can be present in measurable concentrations up to 1.5 years after the application.
Ingrid Kreissig - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal Triamcinolone Acetonide for treatment of intraocular proliferative exudative and neovascular diseases
Progress in Retinal and Eye Research, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, R F DegenringAbstract:Abstract Within the last three years, Triamcinolone Acetonide has increasingly been applied intravitreally as treatment option for various intraocular neovascular edematous and proliferative disorders. The best response in terms of gain in visual acuity after the intravitreal injection of Triamcinolone Acetonide was found in eyes with intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. Visual acuity increased and degree of intraocular inflammation decreased in eyes with various types of non-infectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis–Behcet's disease. Intravitreal Triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularization and proliferative ischemic retinopathies. Possibly, intravitreal Triamcinolone may be helpful as adjunct therapy for exudative age-related macular degeneration, possibly in combination with photodynamic therapy. In eyes with chronic, therapy resistant, ocular hypotony, intravitreal Triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal Triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataractogenesis, postoperative infectious and non-infectious endophthalmitis, and pseudo-endophthalmitis. Intravitreal Triamcinolone injection can be combined with other intraocular surgeries including cataract surgery. Cataract surgery performed some months after the injection does not show a markedly elevated rate of complications. If vision increases and eventually decreases again after an intravitreal Triamcinolone Acetonide injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of Triamcinolone depended on the dosage given. Given in a dosage of about 20 mg to non-vitrectomized eyes, the duration of the effect and of the side-effects was 6–9 months. Intravitreal Triamcinolone Acetonide may offer a possibility for adjunctive treatment of intraocular edematous and neovascular disorders. One has to take into account the side-effects and the lack of long-term follow-up observations.
-
intraocular pressure elevation after intravitreal Triamcinolone Acetonide injection
Ophthalmology, 2005Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone Acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone Acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone Acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone Acetonide therapy.
-
branch retinal vein occlusion treated by intravitreal Triamcinolone Acetonide
Eye, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Bernd A Kamppeter, Imren Akkoyun, R F DegenringAbstract:To evaluate the effect of intravitreal Triamcinolone Acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20–25 mg of Triamcinolone Acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7±4.4 months. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27±0.11 preoperatively to a best postoperative visual acuity of 0.45±0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18±0.18 to 0.13±0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29±0.09 to 0.53±0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Intravitreal injection of Triamcinolone Acetonide can increase visual acuity in patients with branch retinal vein occlusion.
-
Duration of the effect of intravitreal Triamcinolone Acetonide as treatment for diffuse diabetic macular edema
American journal of ophthalmology, 2004Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Bernd A Kamppeter, Imren AkkoyunAbstract:Abstract Purpose To evaluate the duration of the effect of intravitreal Triamcinolone Acetonide on visual acuity in patients with diffuse diabetic macular edema. Design Clinical interventional case series. Methods Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg Triamcinolone Acetonide. Mean follow-up time was 13.2 ± 6.0 months (6.03–25.2 months). Results Visual acuity and intraocular pressure began to increase significantly ( P = .003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection. Conclusions The effect of an intravitreal injection of approximately 20- to 25-mg Triamcinolone Acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal Triamcinolone Acetonide for the treatment of diffuse diabetic macular edema.
-
intravitreal Triamcinolone Acetonide for pseudophakic cystoid macular edema
American Journal of Ophthalmology, 2003Co-Authors: Jost B Jonas, Ingrid Kreissig, R F DegenringAbstract:Abstract Purpose To report the clinical outcome of patients undergoing intravitreal injection of Triamcinolone Acetonide as treatment of long-standing cystoid macular edema after phacoemulsification. Design Prospective clinical interventional cases series studies. Methods The study included five patients suffering from cystoid macular edema after cataract surgery. They received an intravitreal injection of 25-mg crystalline Triamcinolone Acetonide transconjunctivally with topical anesthesia. Results In the follow-up period of 6.6 ± 4.1 months, visual acuity increased from 0.26 ± 0.13 to a mean maximal visual acuity of 0.60 ± 0.19. For all patients, visual acuity improved during the follow-up by at least 0.20. Two (40%) patients developed intraocular pressure values higher than 21 mm Hg, which could be controlled by topical antiglaucomatous treatment. Conclusions Intravitreal Triamcinolone Acetonide may be a therapeutic option for long-standing cystoid macular edema after cataract surgery.
Jb Jonas - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal bevacizumab vs Triamcinolone Acetonide for macular oedema due to central retinal vein occlusion
Eye, 2010Co-Authors: J Hou, Yong Tao, Yanrong Jiang, Jb JonasAbstract:Intravitreal bevacizumab vs Triamcinolone Acetonide for macular oedema due to central retinal vein occlusion
-
intravitreal Triamcinolone Acetonide for treatment of intraocular proliferative exudative and neovascular diseases
Progress in Retinal and Eye Research, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, R F DegenringAbstract:Abstract Within the last three years, Triamcinolone Acetonide has increasingly been applied intravitreally as treatment option for various intraocular neovascular edematous and proliferative disorders. The best response in terms of gain in visual acuity after the intravitreal injection of Triamcinolone Acetonide was found in eyes with intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. Visual acuity increased and degree of intraocular inflammation decreased in eyes with various types of non-infectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis–Behcet's disease. Intravitreal Triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularization and proliferative ischemic retinopathies. Possibly, intravitreal Triamcinolone may be helpful as adjunct therapy for exudative age-related macular degeneration, possibly in combination with photodynamic therapy. In eyes with chronic, therapy resistant, ocular hypotony, intravitreal Triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal Triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataractogenesis, postoperative infectious and non-infectious endophthalmitis, and pseudo-endophthalmitis. Intravitreal Triamcinolone injection can be combined with other intraocular surgeries including cataract surgery. Cataract surgery performed some months after the injection does not show a markedly elevated rate of complications. If vision increases and eventually decreases again after an intravitreal Triamcinolone Acetonide injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of Triamcinolone depended on the dosage given. Given in a dosage of about 20 mg to non-vitrectomized eyes, the duration of the effect and of the side-effects was 6–9 months. Intravitreal Triamcinolone Acetonide may offer a possibility for adjunctive treatment of intraocular edematous and neovascular disorders. One has to take into account the side-effects and the lack of long-term follow-up observations.
-
branch retinal vein occlusion treated by intravitreal Triamcinolone Acetonide
Eye, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Bernd A Kamppeter, Imren Akkoyun, R F DegenringAbstract:To evaluate the effect of intravitreal Triamcinolone Acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20–25 mg of Triamcinolone Acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7±4.4 months. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27±0.11 preoperatively to a best postoperative visual acuity of 0.45±0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18±0.18 to 0.13±0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29±0.09 to 0.53±0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Intravitreal injection of Triamcinolone Acetonide can increase visual acuity in patients with branch retinal vein occlusion.
-
intravitreal Triamcinolone Acetonide as treatment for extensive exudative retinal detachment
British Journal of Ophthalmology, 2004Co-Authors: Jb JonasAbstract:Coats’ disease or entities like Coats’ disease are characterised by a marked exudative retinal detachment with leakage of peripheral retinal vessels, pronounced subretinal deposition of lipids, and eventual progression to total retinal detachment. In some situations, iris neovascularisation can occur, suggesting an angiogenetic component in the course of the disease. In view of the subretinal exudation from the leaking retinal vessels and the possibly neovascular aspect in the disease process, the purpose of this study was to evaluate whether intravitreal Triamcinolone Acetonide may be helpful in the treatment of Coats’ like diseases. Intravitreal Triamcinolone Acetonide has recently been shown to have a pronounced anti-oedematous and possibly anti-angiogenic effect in diseases such as diffuse diabetic macular oedema, proliferative diabetic retinopathy, chronic pre-phthisical ocular …
-
intraocular pressure after intravitreal injection of Triamcinolone Acetonide
British Journal of Ophthalmology, 2003Co-Authors: Jb Jonas, Ingrid Kreissig, R F DegenringAbstract:Aim: To investigate the intraocular pressure (IOP) response after intravitreal injections of Triamcinolone Acetonide as treatment of intraocular neovascular or oedematous diseases. Methods: The prospective consecutive non-comparative interventional case series study included 71 patients (75 eyes) with progressive exudative age related macular degeneration (n = 64 eyes) or diffuse diabetic macular oedema (n = 11 eyes), who received an intravitreal injection of 25 mg Triamcinolone Acetonide. Mean follow up time was 6.86 (SD 2.52) months (range 3.1–14.47 months). Results: IOP increased significantly (p<0.001) from 15.43 (3.26) mm Hg preoperatively to a mean maximum of 23.38 (8.37) mm Hg (range 13–64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about 2 months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalised about 6 months after the injection, without further medication. Eyes undergoing repeatedly intravitreal injections of Triamcinolone Acetonide showed only an elevation of IOP, if after the first injection a rise of IOP had occurred. Conclusions: After intravitreal injections of 25 mg of Triamcinolone Acetonide, an IOP elevation can develop in about 50% of eyes, starting about 1–2 months after the injection. In the vast majority, IOP can be normalised by topical medication, and returns to normal values without further medication about 6 months after the injection.
Bernd A Kamppeter - One of the best experts on this subject based on the ideXlab platform.
-
intraocular pressure elevation after intravitreal Triamcinolone Acetonide injection
Ophthalmology, 2005Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone Acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone Acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone Acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone Acetonide therapy.
-
branch retinal vein occlusion treated by intravitreal Triamcinolone Acetonide
Eye, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Bernd A Kamppeter, Imren Akkoyun, R F DegenringAbstract:To evaluate the effect of intravitreal Triamcinolone Acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20–25 mg of Triamcinolone Acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.7±4.4 months. In the study group, mean visual acuity increased significantly (P=0.02) from 0.27±0.11 preoperatively to a best postoperative visual acuity of 0.45±0.27. Visual acuity measurements determined 1 month after the injection were significantly (P=0.027) higher than baseline values. Nine (90%) eyes gained in visual acuity, with six (60%) eyes showing an increase in visual acuity of at least two Snellen lines. In the ischaemic subgroup, visual acuity did not change significantly (0.18±0.18 to 0.13±0.04; P=0.66), while, in the nonischaemic subgroup, visual acuity increased significantly (P=0.012) from the baseline value to the best postoperative measurement (0.29±0.09 to 0.53±0.24). In the control group, baseline visual acuity and best visual acuity during the follow-up did not vary significantly (P=0.27). Comparing the study and control groups with each other, the gain in visual acuity was significantly higher in the study group at 1 month (P=0.016) and 2 months (P=0.012) after baseline. Intravitreal injection of Triamcinolone Acetonide can increase visual acuity in patients with branch retinal vein occlusion.
-
inter eye difference in diabetic macular edema after unilateral intravitreal injection of Triamcinolone Acetonide
American Journal of Ophthalmology, 2004Co-Authors: Jost B Jonas, B Harder, Bernd A KamppeterAbstract:Purpose To report on visual outcome of patients receiving intravitreal Triamcinolone Acetonide for treatment of diffuse diabetic macular edema. Design Prospective, comparative clinical interventional study. Methods setting: Institutional. patient population: The study included 25 consecutive patients (50 eyes) with bilateral diabetic macular edema. intervention procedure: Unilateral intravitreal injection of about 20 mg Triamcinolone Acetonide into the eye (study group) more severely affected by diabetic maculopathy. The contralateral eyes served as control group. Mean follow-up was 7.1 ± 4.1 months. main outcome measure: Visual acuity, intraocular pressure. Results In the study group, visual acuity increased significantly ( P ≤ .001) by 3.0 ± 2.6 Snellen lines to a peak at two to six months after the injection, and decreased significantly ( P = .001) towards the end of follow up. At the end of follow-up, visual acuity was higher, not significantly ( P = .18) higher, than at baseline. An increase in visual acuity was found in 23 eyes (92%). In the control group, differences between visual acuity at baseline and at any of the re-examinations during follow-up were not significant ( P > .10). In an intra-individual inter-eye comparison, gain in visual acuity was significantly ( P Conclusions Intravitreal Triamcinolone Acetonide may temporarily increase visual acuity in eyes with diabetic macular edema.
-
Duration of the effect of intravitreal Triamcinolone Acetonide as treatment for diffuse diabetic macular edema
American journal of ophthalmology, 2004Co-Authors: Jost B Jonas, Ingrid Kreissig, R F Degenring, Bernd A Kamppeter, Imren AkkoyunAbstract:Abstract Purpose To evaluate the duration of the effect of intravitreal Triamcinolone Acetonide on visual acuity in patients with diffuse diabetic macular edema. Design Clinical interventional case series. Methods Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg Triamcinolone Acetonide. Mean follow-up time was 13.2 ± 6.0 months (6.03–25.2 months). Results Visual acuity and intraocular pressure began to increase significantly ( P = .003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection. Conclusions The effect of an intravitreal injection of approximately 20- to 25-mg Triamcinolone Acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal Triamcinolone Acetonide for the treatment of diffuse diabetic macular edema.
